Clinical Update: Promising Results From...
Nov. 16, 2022
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
PACT Pharma
Company Type: Therapeutics
Main focus: Engineering of T cells
Company stage: Pre-clinical
Diseases: Immune-oncology
Genome-editing tool: CRISPR/Cas
Funding stage: Series C
Location: Hayward, California, USA
Website: https://pactpharma.com
Pipeline: pactpharma.com/programs/
Partners:
PACT is a clinical-stage privately held biopharmaceutical company pioneering individualised and off-the-shelf, non-viral precision genome engineered, tumour-specific T cell receptor (TCR) T cell therapies for the treatment of patients with solid cancers.
Tags
Clinical Trials
IND Enabling
Phase I
Phase II
Phase III
